Personalized medicine milestone: FDA greenlights Abbott’s Hep C genotype test

News that Abbott Laboratories (NYSE: ABT) Hepatitis C test has been cleared by the U.S. Food and Drug Administration was a significant milestone for personalized medicine. The Abbott RealTime HCV Geno…
Read the full story: MedCity News